AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04223973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lab A1C
Description: Measure of Lab A1C at baseline and end of study
Study NCT04223973 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lab A1C
Description: Measure of Lab A1C at baseline and end of study
Study NCT04368676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Description: The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
Study NCT04368676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
Study NCT02888613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mini laparotomy
Description: The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
Study NCT02888613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mini lumbotomy
Description: After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
Study NCT05169255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic administration
Description: Individuals received either azithromycin or amoxicillin for 3 or 7 days
Study NCT00261456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSA test
Description: Patients tested for their level of Prostate Specific Antigen.
Study NCT00261456 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate Biopsy
Description: A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
Study NCT02465515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Description: Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
Study NCT02465515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Description: Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
Study NCT02465515 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albiglutide matching placebo
Description: Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
Study NCT02573688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Therapy
Description: The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
Study NCT02014571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
Study NCT02852707 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chronic exposure to unilateral overhead sports activity
Description: Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports).
Study NCT01019616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/anthracycline
Description: standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
Study NCT02852707 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chronic exposure to bilateral overhead sports activity
Description: Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports).
Study NCT02852707 — intervention group
Intervention type: BEHAVIORAL
Intervention: Not exposed
Description: People not engaged in regular sports competition/exercise training.
Study NCT02533167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin
Description: initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
Study NCT02014571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
Study NCT02620657 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study NCT01688518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heated Lidocaine/Tetracaine Patch
Study NCT01688518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Lidocaine Patch
Study NCT01817530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: oral coated tablet
Study NCT01817530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet
Study NCT01817530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.1 mg norethindrone acetate
Description: oral hard capsule
Study NCT01817530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol / 0.5 mg norethindrone acetate
Description: oral hard capsule
Study NCT02311504 — intervention group
Intervention type: DEVICE
Intervention: OCT examination
Study NCT01817530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/NETA placebo
Description: oral hard capsule
Study NCT01817530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2/NETA placebo
Description: oral hard capsule
Study NCT06442410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system
Description: Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
Study NCT06442410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management (CMM)
Description: The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
Study NCT06442410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Medical Management (CMM)
Description: The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
Study NCT01044875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pan retinal photocoagulation laser treatment
Description: Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
Study NCT02538029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Group
Description: Performing motor-motor or motor-cognitive tasks at the same time.
Study NCT02538029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Task Group
Description: Performing motor or cognitive tasks alone.
Study NCT00492141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
Study NCT00492141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9-NC
Description: Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3.
Study NCT04335097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensors
Description: Sensor that detect vital signs
Study NCT04760821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
Study NCT01861860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS™ Element long stent
Description: Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
Study NCT01673217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT01673217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 peptide vaccine
Description: Given SC
Study NCT01673217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT01673217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT01673217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC
Study NCT01673217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01673217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies
Study NCT01673217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT01673217 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT03436485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-208
Description: co-administered with glucocorticoid and fludrocortisone, orally daily
Study NCT01673217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01673217 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study NCT01673217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT02702219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility of the hamstrings muscles
Study NCT02702219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobility of the hamstrings muscles
Study NCT00507923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Wear actigraph
Study NCT00507923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph
Description: Wear actigraph
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Diary
Description: Complete sleep diary
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Diary
Description: Complete sleep diary
Study NCT00507923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participate in stretching sessions
Study NCT00507923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participate in Tibetan yoga
Study NCT00713856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Custom PRK with iris registration
Description: PRK
Study NCT00713856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PRK
Description: PRK
Study NCT00214760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PGET
Description: resolbable liner
Study NCT00214760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA
Description: cement liner
Study NCT02777333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
Study NCT02597231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is the dietary supplement we are using in delirium prevention.
Study NCT02597231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive a matching placebo pill.
Study NCT00981240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR103168
Description: Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion
Study NCT02210650 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Symptomatic stone removal
Description: Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
Study NCT02210650 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Asymptomatic kidney stones and ureteral stone removed
Description: Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
Study NCT03436485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: orally
Study NCT03205527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground slip perturbation training
Description: Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
Study NCT02166463 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin Sulfate
Description: Given IV or SC
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Given IV
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05686031 — intervention group
Intervention type: OTHER
Intervention: No interventions were done between groups
Description: No interventions were done between groups
Study NCT02540109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix Medical, Active)
Description: Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
Study NCT02540109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix Medical, Sham)
Description: Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
Study NCT00895232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort I
Study NCT00895232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort II
Study NCT00895232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort III